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ABBREVIATIONS:
CAD – coronary artery disease
CCS – Canadian Cardiovascular Society
CMD – coronary microcirculatory disease
CVD – cardiovascular disease
ETT – exercise treadmill test 
PLR – platelet-lymphocyte ratio
NLR – neutrophil-lymphocyte ratio
NA – not applicable
FFR – fractional flow reserve
CFR – coronary flow reserve
IMR – index of microcirculatory resistance
SPECT – single photon emission computed tomography
PCI – percutaneous coronary intervention
CABG – coronary artery bypass grafting
SD – standard deviation
LVEF – left ventricle ejection fraction
LAD – left anterior descending
LCX – left circumflex branch
RCA – right coronary artery 
MACCE – major adverse cardiac and cardiovascular event
INTRODUCTION
Cardiovascular diseases are leading cause of morbidity and 
mortality throughout the world. According to the literature 
about 30% all deaths worldwide are a result of CVD [1, 2]. Heart 
ischemic disease is the most common diagnosis in this wide, 
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ABSTRACT
Introduction: Index of microcirculatory resistance assessment is an invasive method of measuring coronary microcirculation function. Association between impaired microcirculatory 
function and higher rate of cardiovascular events was proven. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio seem to be a promising parameters to predict coronary 
microcirculatory disease in patients with chronic coronary syndrome.
The aim: To determine neutrophil-lymphocyte ratio and platelet-lymphocyte ratio levels in patients with coronary microcirculatory disease and potential association with 
clinical outcome.
Material and methods: 82 consecutive patients with mean age of 67 years, 67% male, were tested for presence of coronary microcirculatory disease using index of 
microcirculatory resistance. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio were calculated based on admission full blood count. Follow-up with major adverse 
cardiac and cardiovascular events registration was performed (median 24 months).
Results: The study showed significantly higher neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with coronary microcirculatory disease compared to 
control group (3.58±2.61 vs 2.54±1.09 and 164±87.9 vs 124±36.6 respectively). Higher level of platelet-lymphocyte ratio in patients with coronary microcirculatory disease 
results in worse MACCE-free survival. Optimal cut-off values of  neutrophil-lymphocyte ratio and platelet-lymphocyte ratio to detect coronary microcirculatory disease were 
3.2 and 181.3, respectively.
Conclusions: Higher neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with increased index of microcirculatory resistance value. Platelet-lymphocyte 
ratio may be used as a predictor of worse outcome in patients with coronary microcirculatory disease.
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heterogenic group [3, 4]. Cardiac ischemic disease may affect 
both epicardial arteries and coronary microcirculation which 
consists of small vessels arterioles and capillaries [5]. Dysfunc-
tion of coronary microcirculation is associated with increased 
risk of major adverse cardiovascular events including cardiac 
death, stroke, and heart failure [6,7]. Chronic inflammation is 
considered as an important factor in pathophysiology of ath-
erosclerosis [8-10]. Elevated level of inflammatory markers is 
observed in disease of epicardial arteries [11, 12]. Pathogenesis of 
coronary microcirculatory dysfunction is still understudied and 
it remains an interesting clinical issue. Some inflammatory indi-
cators are considered to take a part in coronary microcirculation 
pathology [12, 13]. The neutrophil-to-lymphocyte ratio (NLR) 
and platelet-to-lymphocyte ratio (PLR) have been investigated 
as new markers for cardiovascular prognosis [14-16]. Elevated 
levels of both, NLR and PLR ratio were observed in patients 
with acute coronary syndrome as predictors of worse outcome 
[17]. Neutrophil-to-lymphocyte ratio measured in patients with 
chronic coronary syndrome is connected with higher severity 
of coronary artery disease [18]. To our best knowledge there is 
no data available on NLR and PLR levels according to coronary 
microcirculatory dysfunction in chronic coronary syndrome. 
It was shown that microcirculatory dysfunction is connected 
with higher risk of the cardiovascular events [5, 6]. The index of 
microcirculatory resistance (IMR) measurement is an invasive 
method of coronary microcirculation assessment [19-21]. 
THE AIM
The aim of our study is to investigate if the levels of neu-
trophil-lymphocyte ratio (NLR) and platelet-lymphocyte 
ratio (PLR) are associated with coronary microcirculation 
impairment in patients with chronic coronary syndrome. 
We hypothesize that:
-  levels of neutrophil-lymphocyte ratio (NLR) and plate-
let-lymphocyte ratio (PLR) are elevated in patients with 
Table 1. Baseline characteristics.
All patients  CMD (IMR<25) Control group (IMR<25) P-value
 N=82  N=30  N=52  
Age, mean (SD) [year] 67.0 (8.74)  69.1 (9.74)  65.8 (7.97)  0.128 
Sex male, n (%)  54 (66.7)  20 (69.0)  34 (65.4)  0.935 
SBP, mean (SD) [mmHg]  130 (12.5)  131 (11.1)  129 (13.3)  0.656 
LVEF, mean (SD) [%] 55.1 (11.2)  53.8 (15.1)  55.9 (8.08)  0.582 
Vessel     0.027 *
 LAD, n (%)  39 (47.6)  16 (53.3)  23 (44.2)  
 LCx, n (%)  27 (32.9)  5 (16.7)  22 (42.3)  
 RCA, n (%)  16 (19.5)  9 (30.0)  7 (13.5)  
Diabetes, n (%)  29 (35.4)  9 (30.0)  20 (38.5)  0.595 
Arterial hypertension, n (%)  79 (96.3)  30 (100)  49 (94.2)  0.295 
Smoking, n (%)  12 (16.2)  5 (18.5)  7 (14.9)  0.749 
Medications:
ASA, n (%)  73 (89.0)  24 (80.0) 49 (94.2)  0.068 
B-blocker, n (%)  65 (79.3)  23 (76.7)  42 (80.8)  0.874 
ACEI/ARB, n (%)  72 (88.9)  25 (86.2)  47 (90.4)  0.715 
Dihydropyridine calcium blocker, n (%)  26 (31.7)  14 (46.7)  12 (23.1)  0.049 *
Loop diuretics, n (%)  11 (13.6)  6 (20.7)  5 (9.62)  0.189 
Statin, n (%)  82 (100)  30 (100)  52 (100) NA 
SBP – systolic blood pressure; LVEF – left ventricle ejection fraction; LAD – left anterior descending artery; LCx – left circumflex artery; RCA – right 
coronary artery; ASA – acetylsalicylic acid; b-bloker – beta-adrenolitic drug; ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensyn receptor 
blocker; * statistical significance (p<0,05)
Table 2. Coronary physiology assessment.
All patients CMD (IMR≥25) Control group (IMR<25) P-value
 N=82  N=30  N=52  
FFR, mean (SD) 0.88 (0.05)  0.87 (0.05)  0.88 (0.05)  0.281 
CFR, mean (SD) 2.22 (1.13)  1.82 (0.78)  2.47 (1.25)  0.007 *
IMR, mean (SD) 24.8 (15.4)  39.3 (15.8)  16.0 (5.05)  <0.001*
FFR – fractional flow reserve; CFR – coronary flow reserve; IMR – index of microcirculatory resistance; * statistical significance (p<0,05)
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Table 3. Laboratory results
All patients CMD (IMR≥25) Control group (IMR<25) P-value
 N=82  N=30 N=52  
NLR, mean (SD) 2.92 (1.86)  3.58 (2.61)  2.54 (1.09)  0.045 *
PLR, mean (SD)  139 (63.1)  164 (87.9)  124 (36.6)  0.023 * 
RBC, mean (SD) [*106/uL] 4.70 (0.40)  4.70 (0.43)  4.70 (0.38)  0.974 
HGB, mean (SD) [g/dL] 14.2 (1.42)  14.1 (1.56)  14.2 (1.36)  0.841 
WBC, mean (SD) [*106/uL] 7.01 (1.58)  6.84 (1.42)  7.11 (1.67)  0.439 
PLT, mean (SD) [*106/uL]  222 (50.3)  224 (63.0)  221 (41.8)  0.834 
Creatinine, mean (SD) [umol/L] 83.5 (18.9)  88.7 (23.7)  80.6 (15.0)  0.099 
Glucose, mean (SD) [mmol/L] 6.50 (1.85)  6.50 (1.77)  6.50 (1.92)  0.994 
HbA1c, mean (SD) [%] 6.03 (0.93)  5.69 (0.40)  6.20 (1.08)  0.031 * 
LDL, mean (SD) [mmol/L] 2.77 (1.20)  2.84 (1.29)  2.73 (1.16)  0.697 
HDL, mean (SD) [mmol/L] 1.33 (0.34)  1.33 (0.34)  1.33 (0.35)  0.999 
Total cholesterol, mean (SD) [mmol/L] 4.38 (1.31)  4.51 (1.32)  4.31 (1.31)  0.493 
TG, mean (SD) [mmol/L] 1.54 (0.85)  1.53 (0.98)  1.55 (0.77)  0.934 
LDL – low density lipoprotein; HDL – high density lipoprotein; TG – triglycerides; NLR – neutrophil-lymphocyte ratio; PLR – platelet-lymphocyte ratio; 
CMD coronary microcirculatory disease; IMR – index of microcirculatory resistance; RBC – red blood count; HGB – haemoglobin; WBC – white blood 
count; PLT – platelets; HbA1c – glycated haemoglobin;
* statistical significance (p<0,05)
Fig. 1. Comparison of 
neutrophile-lymphocyte 
ratio (NLR) (A) and platelet-
lymphocyte (PLR) (B) value 
in CMD and control group.
NLR – neutrophil-
lymphocyte ratio;  
PLR – platelet-lymphocyte 
ratio; CMD coronary 
microcirculatory 
disease; IMR – index 
of microcirculatory 
resistance; • statistical 
significance (p<0,05)
Fig. 2. MACCE free survival 
in patients with CMD and 
low/high NLR (A) and 
PLR (B) levels (Kaplan-
Meier estimator).
PLR – platelet-lymphocyte  
ratio; NLR – neutrophil-
lymphocyte ratio;  
* statistical significance 
(p<0,05) 
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chronic coronary syndrome and coronary microcircula-
tory impairment compared to patients with chronic cor-
onary syndrome and normal microcirculatory function
-  patients with higher level of neutrophil-lymphocyte ratio 
(NLR) and platelet-lymphocyte ratio (PLR) have worse 
survival probability compared to patients with lower 
NLR and PLR level in group of coronary microcircula-
tory disease
MATERIAL AND METHODS
This was a prospective study. We enrolled 82 consecutive, 
adult patients admitted to The Department of Interven-
tional Cardiology in The John Paul II Hospital, Cracow, 
Poland. Patients had symptoms of stable angina, grade 
I – III according to the Canadian Cardiovascular Scale 
(CCS). Evidence of ischemia was proved with non invasive 
stress tests: exercise treadmill test (ETT), stress echocardi-
ography or single photon emission computed tomography 
(SPECT). We excluded patients with diagnosed malignant 
neoplasm, history of prior percutaneous coronary angio-
plasty or coronary artery bypass grafting, history of chronic 
inflammatory disease, infectious disease or active bleeding, 
expected survival less then 1 year. 
Vital sings such as arterial blood pressure, heart rate 
were collected. Risk factors including arterial hypertension, 
diabetes, smoking were recorded. We gathered informa-
tion about current medical treatment. Blood samples 
(2 ml) were taken to test-tubes with EDTA (full blood 
count measurement) and test-tubes with no anticoagulant 
(chemistry tests). Peripheral full blood count was analyzed 
Coulter optical measurement system (Beckman Coulter, 
United States). Neutrophil-lymphocyte ratio (NLR) and 
platelet-lymphocyte ratio (PLR) were counted. In cardiac 
ultrasound (Philips XC50, Holland) left ventricle ejection 
fraction was measured with Simpson’s biplane method. 
The patients were screened for presence of intermediate 
stenosis of epicardial arteries. We considered coronary artery 
stenosis of 50-90% as a borderline lesion [22]. If present, we 
performed full coronary physiology assessment using Pres-
sure Wire X (Abbott Vascular, Santa Clara, California, US) 
connected to computer by Wi-Fi. Measurements of mean 
transit time were initially made in resting conditions. Than 
we induced maximal hyperemia with continuous intrave-
nous infusion of adenosine (140 ug/kg/min) and repeated 
transit mean time registration. FFR was calculated as a ratio 
between blood pressure in distal part of examined coronary 
artery and blood pressure in aorta at maximal hyperemia. 
Result of ratio between resting and hyperemic transit mean 
time was CFR. IMR value was calculated by multiplying 
mean transit time of room temperature saline through 
coronary artery and distal coronary artery pressure. All 
measurements registered during procedure were automat-
ically sent to Coroflow software (Coroventis AB, Uppsala, 
Sweden) which performed calculations of fractional flow 
reserve (FFR), coronary flow reserve (CFR) and index of 
microcirculatory resistance (IMR) [23]. Patients with pos-
itive result of fractional flow reserve (FFR 0.8) underwent 
coronary revascularization and were excluded from this 
study. If more than one vessel was examined in one patient, 
results from all vessels were analyzed. The study protocol re-
ceived positive opinion from Jagiellonian University Ethical 
Committee (nr 122.6120.262.2015).
FOLLOW-UP
Clinical follow was made at 24 months. Major adverse 
cardiac and cardiovascular event (MACCE) as a primary 
composite end point was assessed, which was defined as 
myocardial infarction, percutaneous coronary angioplasty, 
stroke, all cause-death.
STATISTICAL METHODS
Statistical analysis was performed using IBM SPSS Statistics 
(version 25) and R language (R-Studio, version 8.9) packages 
for Windows. Categorical data were described as percentages, 
while continuous data were described as mean (± SD). Normal 
distribution was tested by Kolmogorov-Smirnov test. Categori-
cal variables were compared using chi-squared test. Continuous 
Fig. 3. ROC curves for NLR (A) 
and PLR (B) to detect CMD.
ROC – receiver operating 
characterisrtic;  
PLR – platelet-lymphocyte 
ratio; NLR – neutrophil-
lymphocyte ratio; CMD 
coronary microcirculatory 
disease.
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variables were compared by Mann-Whitney or t-student tests. 
The optimal cut off point for multiple continuous variables was 
determined using the maximally selected rank statistics from 
the ‘maxstat’ R package. Survival probability was evaluated 
using Kaplan-Meier survival estimators. A value of P < 0.05 
was established as statistical significant. Logistic mixed effects 
regression models were built, using NLR, PLR and common 
atherosclerosis risk factors (i.e. diabetes, smoking status, sex) 
Table 4. Logistic regression models.
  NLR PLR
Predictors Odds Ratios CI p Odds Ratios CI p
(Intercept) 0.16 0.03 – 0.78 0.023 * 0.05 0.01 – 0.48 0.010 *
NLR increase of 1 unit 1.50 1.05 – 2.13 0.026 *
Present smoker 1.54 0.35 – 6.70 0.563 2.07 0.47 – 9.12 0.338
Diabetes 0.84 0.27 – 2.59 0.762 0.84 0.27 – 2.57 0.756
Male sex 1.03 0.32 – 3.35 0.959 1.57 0.47 – 5.26 0.461
PLR increase of 10 units 1.16 1.03 – 1.31 0.016 *
NLR – neutrophil-lymphocyte ratio; PLR – platelet-lymphocyte ratio;
* statistical significance (p<0,05) 
Table 5. Supplementary table. Baseline characteristics.
All patients IMR- CFR- IMR- CFR+ IMR+ CFR- IMR+ CFR + P-value
N=76 N=32 N=15 N=7 N=22
Age, mean (SD) [year] 67.4 (8.65) 66.6 (8.06) 66.6 (7.76) 67.6 (9.57) 69.1 (10.0) 0.738
Sex male, n (%) 49 (65.3) 16 (50.0) 13 (86.7) 6 (85.7) 14 (66.7) 0.055
SBP, mean (SD) [mmHg] 130 (12.1) 128 (12.9) 134 (13.1) 132 (10.5) 131 (10.8) 0.500
LVEF, mean (SD) [%] 54.8 (11.5) 55.8 (8.05) 54.8 (9.74) 60.0 (15.4) 51.6 (14.9) 0.540
Vessel: 0.023
 LAD, n (%) 36 (47.4) 17 (53.1) 5 (33.3) 5 (71.4) 9 (40.9)
 LCx, n (%) 24 (31.6) 10 (31.2) 9 (60.0) 0 (0.00) 5 (22.7)
 RCA, n (%) 15 (19.7) 5 (15.6) 1 (6.67) 1 (14.3) 8 (36.4)
Diabetes, n (%) 27 (35.5) 11 (34.4) 8 (53.3) 2 (28.6) 6 (27.3) 0.419
Arterial hypertension, n (%) 74 (97.4) 30 (93.8) 15 (100) 7 (100) 22 (100) 0.753
Smoking, n (%) 12 (17.1) 4 (13.3) 3 (21.4) 1 (14.3) 4 (21.1) 0.899
Medications:
ASA, n (%) 68 (89.5) 29 (90.6) 15 (100) 6 (85.7) 18 (81.8) 0.311
B-blocker, n (%) 61 (80.3) 28 (87.5) 11 (73.3) 5 (71.4) 17 (77.3) 0.521
ACEI/ARB, n (%) 66 (88.0) 28 (87.5) 14 (93.3) 5 (71.4) 19 (90.5) 0.515
Dihydropyridine calcium blocker, n (%) 26 (34.2) 9 (28.1) 3 (20.0) 2 (28.6) 12 (54.5) 0.126
Loop diuretics, n (%) 10 (13.3) 3 (9.38) 2 (13.3) 1 (14.3) 4 (19.0) 0.769
Statin, n (%) 76 (100) 32 (100) 15 (100) 7 (100) 22 (100) NA
SBP – systolic blood pressure; LVEF – left ventricle ejection fraction; LAD – left anterior descending artery; LCx – left circumflex artery; RCA – right 
coronary artery; ASA – acetylsalicylic acid; b-bloker – beta-adrenolitic drug; ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensyn receptor 
blocker; * statistical significance (p<0,05)
Table 6. Supplementary table. Coronary physiology assessment.
All patients  IMR- CFR-  IMR- CFR+  IMR+ CFR- IMR+ CFR + P-value
 N=76  N=32  N=15  N=7  N=22  
FFR, mean (SD) 0.88 (0.05) 0.89 (0.05) 0.88 (0.05) 0.86 (0.04) 0.87 (0.05)  0.474 
CFR, mean (SD) 2.22 (1.13) 3.02 (1.14) 1.30 (0.28) 2.99 (0.55) 1.45 (0.36) <0.001* 
IMR, mean (SD) 25.1 (15.4) 16.2 (4.95) 16.3 (5.07) 31.5 (2.99) 41.9 (17.5) <0.001*
FFR – fractional flow reserve; CFR – coronary flow reserve; IMR – index of microcirculatory resistance; * statistical significance (p<0,05)
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as fixed factors and type of tested vessel as random factor. This 
approach was used as flow in coronary arteries varies according 
to type of vessel (i.e. right vs left coronary artery) and the area 
of myocardium supplied by particular vessel [24].
RESULTS
The study population consists of 82 consecutive patients 
who underwent elective coronary angiography in chronic 
coronary syndrome and did not meet exclusion criteria. 
Whole population was divided into 2 groups according to 
result of the index of microcirculatory resistance. Patients 
included to group of normal coronary microcirculatory 
function (control group, 52 objects) had IMR < 25. Patients 
in coronary microcirculatory dysfunction group (CMD 
group, 30 objects) had IMR ≥ 25. Baseline characteristics 
was shown in table 1. Age distribution in both groups was 
similar (69.1 ± 9.74 vs 65.8 ± 7.97 years). Number of male 
patients did not differ in both groups (69% vs 65%). There 
was no significant difference in systolic blood pressure 
(131 ± 11.1mmHg vs 129 ± 13.3mmHg) and left ventricle 
ejection fraction (53.8 ± 15.1% vs 55.9 ± 8%) between both 
groups. 52 main coronary vessels in control group and 30 
vessels in CMD group were assessed, while the left anterior 
descending artery was the most often examined vessel. 
Both groups did not differ significantly in risk factors of 
coronary artery disease and taken medications despite 
dihydropyridine calcium channel blockers which were 
used more often in CMD group (46.7% vs 23.1%) (Table 1).
Fractional flow reserve (FFR) result was similar in both 
groups (0.87±0.05 vs 0.88±0.05). Coronary flow reserve (CFR) 
was significantly higher in control group compared to CMD 
group (2.47 ± 1.25 vs 1.82 ± 0.78; P = 0.007). The result of index 
of microcirculatory resistance was criterion of groups distinc-
tion as we mentioned previously and it was significantly higher 
in CMD group (39.3 ± 15.8 vs 16.0 ± 5.05; P<0.001) (Table 2). 
Level of serum low-density-lipoprotein (LDL) was lower 
in control group (2.84 ± 1.29 vs 2.73 ± 1.16 mmol/l) how-
ever difference was not statistically significant (P > 0.05). 
The results of neutrophil-lymphocyte ratio (NLR) and 
Table 7. Supplementary table. Laboratory results.
All patients  IMR- CFR-  IMR- CFR+  IMR+ CFR-  IMR+ CFR + P-value
 N=76  N=32  N=15  N=7  N=22  
NLR, mean (SD) 2.28 2.34 2.14 2.02 2.82  0.220 
PLR, mean (SD)  119  112  107  117  132  0.161 
RBC, mean (SD) [*106/uL] 4.69 (0.39) 4.64 (0.41) 4.74 (0.29) 4.52 (0.46) 4.78 (0.40)  0.352 
HGB, mean (SD) [d/dL] 14.2 (1.44) 14.0 (1.47) 14.4 (1.19) 13.9 (1.20) 14.3 (1.64)  0.704 
WBC, mean (SD) [*106/uL] 6.95 (1.60) 7.31 (1.85) 6.34 (1.16) 6.98 (1.27) 6.83 (1.51)  0.273 
PLT, mean (SD) [*106/uL]  222 (51.0) 224 (42.1) 214 (42.9) 222 (56.9) 226 (66.7)  0.907 
Creatinine, mean (SD) [umol/L] 83.9 (19.4) 82.4 (16.7) 78.4 (12.9) 86.9 (11.2) 88.8 (27.1)  0.407 
Glucose, mean (SD) [mmol/l] 6.58 (1.89) 6.39 (1.89) 7.21 (2.08) 6.63 (1.51) 6.43 (1.90)  0.578 
HbA1c, mean (SD) [%] 6.06 (0.95) 6.27 (0.91) 6.25 (1.41) 5.77 (0.42) 5.65 (0.42)  0.316 
LDL, mean (SD) [mmol/L] 2.72 (1.19) 2.75 (1.28) 2.47 (0.69) 2.17 (0.83) 3.02 (1.38)  0.307 
HDL, mean (SD) [mmol/L] 1.31 (0.32) 1.28 (0.32) 1.31 (0.30) 1.26 (0.37) 1.36 (0.34)  0.841 
Tchol, mean (SD) [mmol/L] 4.32 (1.27) 4.27 (1.39) 4.06 (0.78) 3.77 (0.94) 4.73 (1.39)  0.234 
TG, mean (SD) [mmol/L] 1.57 (0.87) 1.68 (0.82) 1.41 (0.72) 1.43 (0.37) 1.58 (1.13)  0.766 
LDL – low density lipoprotein; HDL – high density lipoprotein; TG – triglycerides; NLR – neutrophil-lymphocyte ratio; PLR – platelet-lymphocyte ratio; 
CMD coronary microcirculatory disease; IMR – index of microcirculatory resistance; RBC – red blood count; HGB – haemoglobin; WBC – white blood 
count; PLT – platelets; HbA1c – glycated haemoglobin;
* statistical significance (p<0,05)
Table 8. Supplementary table. Follow-up endpoints.
All patients CMD (IMR<U+2265>25) Control group (IMR<25) p-value
N=80 N=30 N=50 
Hospitalization, n (%) 25 (31.2) 8 (26.7) 17 (34.0) 0.663
CVD hospitalization, n (%) 19 (23.8) 5 (16.7) 14 (28.0) 0.378
AMI, n (%) 6 (8.45) 2 (6.90) 4 (9.52) 1.000
TVR, n (%) 6 (10.3) 2 (8.33) 4 (11.8) 1.000
MACCE, n (%) 24 (30.0) 8 (26.7) 16 (32.0) 0.801
CVD hospitalization - cardiovascular disease hospitalization; AMI - acute myocardial infarction; TVR - target vessel revascularization; MACCE - major adverse 
cardiac and cardiovascular event
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detailed diagnostics in patient with coronary artery disease 
led to better treatment results, as in that study an invasive 
diagnostics in patients with chronic coronary syndrome 
did not stop on coronary angiography only. Patients have 
also undergone complex functional assessment of coronary 
circulation including provocative test with acetylcholine to 
detect artery overreactivity. Using this approach coronary 
microvascular angina or vasospastic angina were diagnosed 
and appropriate medications were advised. As a result sig-
nificant reduction of angina symptoms, increase of exertion 
tolerance and improvement of quality of life were observed 
as compared with control group, in which only coronary 
angiography was performed [29]. 
In our study we propose evaluation of novel inflamma-
tory markers, the neutrophil-lymphocyte ratio (NLR) and 
platelet-lymphocyte ratio (PLR) as a tool useful in process 
of qualification of patients with coronary artery disease to 
complex invasive diagnostics of coronary circulation. NLR 
and PLR have good specificity to exclude coronary micro-
circulatory disease, however sensitivity to detect CMD 
remains low. Even though, utilization of those parameters 
might help clinicians to select a group of patients with 
indications for complex coronary circulation assessment, 
functional examination and provocative testing.
Further investigation is needed to explore possible cor-
relation between NLR and PLR with other, more specific 
inflammatory markers assessed in patients with coronary 
microvascular disease.
STUDY LIMITATIONS
This is single-centre study, whole population was enrolled in 
one cardiology department. We make an effort so as patients 
were referred to our department by different physicians. 
Despite patients were diagnosed and treated by few separate 
teams, whole group followed the same protocol described 
in methodology chapter. The population finally included 
and analyzed was not large. We considered different clinical 
situations and diseases that may affect result of full blood 
count. Possible fluctuations of lymphocyte and neutrophil 
counts may be result of asymptomatic infections. Numerous 
disorders might be a reason for thrombocytopenia. Decreased 
thrombocyte production, i.e. ferrum/folic acid/ vitamin B12 
deficiency, bone marrow diseases, congenital thrombocytope-
nia or increased thrombocyte destruction, i.e. hemolysis and 
side effects of medications. Active bleeding, alcohol addiction, 
chronic inflammatory diseases may result in thrombocytosis. 
Every patient with diagnosis that may affect result of white 
count or platelet count was excluded from this study. In our 
study correlation between PLR, NLR and other more specific 
inflammatory indicators was not tested.
CONCLUSIONS
In this study we observed higher level of inflammatory mark-
ers: neutrophil-lymphocyte ratio (NLR) and platelet-lympho-
cyte ratio (PLR) in patients with chronic coronary syndrome 
and elevated index of microcirculatory resistance, as com-
platelet-lymphocyte ratio (PLR) were significantly higher 
in CMD group (respectively 3.58 ± 2.61 vs 2.54 ± 1.09; P 
= 0.045 for NLR and 164 ± 87.9 vs 124 ± 36.6; P = 0.023 
for PLR) (Table 3, Fig. 1).
Median length of follow-up in whole studied population 
was 24 months, 22.9 months in CMD group and 24.6 
months in control group. 
Based on mixed effects logistic regression the increased 
NLR or PLR values were associated with increased proba-
bility od microcirculatory dysfunction, with OR 1.5 (95% 
CI: 1.05 – 2.13; P < 0.05) and 1.16 (95% CI 1.03 – 1.31; P 
< 0.05), respectively (Table 4) [25].
Kaplan-Meier estimation showed that MACCE-free 
survival in patient with high PLR level is worse compared 
to patients with low PLR level in group of coronary mi-
crocirculatory disease (P = 0.031) (Fig. 2A). There is no 
significant difference in MACCE-free survival between 
patients with high and low level of NLR in group of coro-
nary microcirculatory disease (P = 0.079), however trend 
is visible (Fig. 2B).
Study population was divided into 4 groups based on 
IMR and CFR normal and abnormal results: IMR-CFR-, 
IMR-CFR+, IMR+CFR-, IMR+CFR+. No significant dif-
ferences between those groups was founded (Table 5-7.)
Area under curve (AUC) for NLR to detect coronary 
microcirculatory disease is 55.5% with cut-off 3.2 and 
specificity of 81.4% (Fig. 3A). 
Similarly AUC for PLR to detect coronary microcircu-
latory disease is 62.8% with cut-off 181.3 and specificity 
of 93% (Fig. 3B). 
DISCUSSION
Epicardial coronary arteries visible in angiography are just 
about 1% of whole coronary circulation. Nearly 99% is 
coronary microcirculation which is not visible in standard 
angiography, as it consists of vessels with lumen diameter less 
than 500µm [5]. Epicardial coronary disease as well as dis-
ease of coronary microcirculation may be a cause of angina 
symptoms and a relevant impact on adverse cardiovascular 
events including cardiac death, stroke, and heart failure 
[5, 6]. Prevalence of coronary microcirculatory disease 
(CMD) is estimated in literature for up to 40% in patients 
with suspected coronary artery disease [26]. Guidelines of 
The European Society of Cardiology for chronic coronary 
syndrome recommend functional assessment in patients 
with intermediate coronary artery stenosis (50-90%) [22]. 
In case of insignificant fractional flow reserve result (i.e. 
FFR > 0.8), coronary flow reserve and index of microcir-
culatory resistance should be measured [22]. Abnormal 
CFR and IMR results are a basis for diagnosis of coronary 
microcirculatory disease [20, 21, 27]. Management of CMD 
differs from treatment of typical epicardial coronary artery 
disease [22]. In CMD treatment more emphasis is put on 
vasodilator medications such as calcium channel blockers 
and long acting nitrates [27, 28]. On the other hand specific 
treatment for CMD is still underdeveloped and this topic 
requires further investigation. According to CORMICA trial 
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pared to patients with normal IMR. Neutrophil-lymphocyte 
ratio (NLR) and platelet-lymphocyte ratio (PLR) might be 
concerned as predictors of coronary microcirculatory disease 
in chronic coronary syndrome and no significant epicardial 
stenosis. Assessment of NLR and PLR may be used to select 
patients who particularly demands complex coronary func-
tional examination during invasive diagnostics. 
What is more, higher levels of NLR and PLR are associat-
ed with worse MACCE-free survival in this group. Further 
investigation is needed in aim to compare neutrophil-lym-
phocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) 
with other, more specific inflammatory markers of CMD.
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